Sphere Fluidics rebrands to Sphere Bio
Supports Company’s global commercial growth, driven by customer demand for integrated life sciences tools and solutions
Sphere Fluidics launches Cyto-Mine Chroma and announces Early Access Program
Researchers invited to gain early access to next-generation platform to optimize functional single-cell analysis workflows across expanded applications in life science R&D
Sphere Fluidics launches Cyto-Cellect® Fc Fusion Assay Kit to expedite cell line development for fusion proteins
Novel assay offers a highly sensitive and specific method to detect recombinant proteins containing the human IgG Fc domain.
Sphere Fluidics strengthens global commercial teams and establishes direct sales and support channel in North America
Significant expansion of global commercial leadership team led by new CEO, Dale Levitzke, to address global demand for the Cyto-Mine Chroma platformCambridge, UK, 14th November 2024: Sph
Sphere Fluidics announces Cyto-Mine Chroma to accelerate and streamline workflows across expanded applications in biotherapeutic discovery and development
Next generation of industry-leading Cyto-Mine platform will offer new capabilities to optimize single-cell analysis workflow efficiency Opens up new, multiplexed assays and applications for antibody discovery and cell line development, and allows entry into
Sphere Fluidics appoints Dr. Alex Dickinson as Non-Executive Director
Appointment of leading technology innovator supports continued commercial development and R&D expansion Previously Senior Executive at Illumina, Co-Founder and former CEO of Helixis and LuxteraCambridge, UK, 10t
Sphere Fluidics awarded Gold accreditation by Investors in People
Internationally-recognized ‘We invest in people’ award is certified recognition of the Company’s care and commitment to its employees globally
Sphere Fluidics launches Cyto-CellectPLUS to accelerate cell line development workflows
Next-generation assay provides a rapid and cost-effective solution to quantify IgG production in single cells
Sphere Fluidics wins The Life Science Company Of The Year Award from the Cambridge Independent
The Cambridge Independent awards were held on the 16th of May 2024, where we were proudly finalists for 2 very prestigious awards: 'Employer of the Year' and 'Life Science Company of the Year'. Being nominated for either of these awards is a great honor for all the team at Sphere Fluidics.
Sphere Fluidics appoints Curtis Nicholson as Director of Sales, EMEA, to support accelerated growth in key markets
Cambridge, UK, 23 May, 2024: Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, today announced the appointment of Curtis Nicholson as Director of Sales for Europe, Middle East, and Africa (EMEA).
Sphere Fluidics appoints Dale Levitzke as Chief Executive Officer
Dale Levitzke joins as Dr. Frank F. Craig, current CEO and co-founder, announces his retirement after leading the Company for 14 years.
Sphere Fluidics appoints Edward Rayner as Non-Executive Director
Ed Rayner joins Sphere Fluidics as new board member to strengthen the Company’s strategic vision and ambition for commercial growth.
Sphere Fluidics appoints Dr. Graeme Daniels as Vice President of Sales and Marketing
Appointment to senior leadership team strengthens the Company’s plans for continued growth to advance its commercial ambitions
Sphere Fluidics’ Cyto-Mine system selected by FairJourney Biologics to advance cell line development workflows
Investment to expand cell line development capabilities and accelerate customer workflows, as part of its diverse and tailored antibody solutions.
Sphere Fluidics expands Cyto-Mine capabilities to meet cGMP requirements for drug manufacture workflows
Latest software updates support FDA 21 CFR Part 11 compliance and a full IQ/OQ package for pharmaceutical quality assurance Additional functionalities extend Cyto-Mine applications into manufacturing operationsSphere Fluidics, a company developin
Sphere Fluidics’ Pico-Mine platform chosen by Biosyntia to accelerate synthetic biology and metabolic workflows
Cambridge, UK, and Copenhagen, Denmark - Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, announces Biosyntia, a biotechnology company focused on synthetic biology and metabolic engineering, has adopted the Pico-Mine® platform within its workflows.
Sphere Fluidics updates brand identity to align with ambitious, global commercial growth strategy
New branding reflects customer-centric approach and showcases pioneering, single cell analysis technology Rebrand follows a period of significant growth for the Company, including key leadership team appointments, state-of-the-art facility expansion, and new scienti
Sphere Fluidics appoints Kenneth Hitchner as Chairman of its Board of Directors
Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has appointed Kenneth Hitchner, BA MBA, as Chairman of its Board of Directors.
Sphere Fluidics begins work with partners on 3DSecret program to investigate mechanisms of metastasis in cancer
3DSecret funded by European Innovation Council’s Pathfinder Open 2022, established under the EU Horizon Europe program Consortium to leverage novel microfluidic technology to culture 3D cancer models for multi-parametric analysis, to inform cancer diagnostic and the
Sphere Fluidics appoints Richard Hammond as Chief Technical Officer
Key appointment forms part of ongoing plans to strengthen senior leadership team and support expansion of microfluidic product range for single cell analysis
Sphere Fluidics opens new laboratory facilities at Granta Park in Cambridgeshire, UK
Cambridge, UK - Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, announces that it has opened a new state-of-the-art facility in Granta Park, Cambridgeshire, UK, to support the Company’s growth. Doubling overall capacity, the laboratories enable the team’s accelerated expansion, and the development of new, innovative products.
Sphere Fluidics closes a $40 million funding round
Sphere Fluidics, a company that has developed and is commercialising single cell analysis systems underpinned by its proprietary picodroplet technology, announced today that it has closed a $40 million (circa £30 million) investment round. The round was led by Sofinnova Partners (Paris, France) and Redmile Group (San Francisco, USA) co-investing on equal terms.
Sphere Fluidics and ClexBio introduce CYTRIX Microfluidic Hydrogel Kit
Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet technology, and ClexBio, a pioneer in solutions for tissue engineering and single-cell techniques, today announced the launch of the biocompatible CYTRIX Microfluidic Hydrogel Kit.
Sphere Fluidics announces enhanced Cyto-Mine capability and performance
Simplified design reduces manufacturing time and offers improved functionality to help streamline antibody discovery, cell line development, cell therapy, and synthetic biology workflows.
Sphere Fluidics and Heriot-Watt University collaborate to develop next generation droplet generator instrumentation
Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, and Heriot-Watt University, a specialist, pioneering Scottish University, today announced they have been awarded a Knowledge Transfer Partnership (KTP) grant from Innovate UK, the UK’s innovation agency.